Current Assets

AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value

Vertex Pharmaceuticals AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value remained flat by 0.0% to $100.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $100.00K to $100.00K.

Analysis

StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ1 2023
Last reportedQ1 2026May 5, 2026
Metric ID: afs_trading_securities_unrealized_loss_12m_plus_fv

Historical Data

10 periods
 Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value$0.00$0.00$0.00$53.80M$3.50M$100.00K$100.00K$100.00K$100.00K$100.00K
QoQ Change————-93.5%-97.1%+0.0%+0.0%+0.0%+0.0%
YoY Change——————-99.8%-97.1%+0.0%+0.0%
Range$0.00 – $53.80M
Avg YoY Growth-49.2%
Median YoY Growth-48.6%
Current Streak4 quarters growth

Frequently Asked Questions

What is Vertex Pharmaceuticals's afs and trading securities - unrealized loss position (>=12 months) fair value?
Vertex Pharmaceuticals (VRTX) reported afs and trading securities - unrealized loss position (>=12 months) fair value of $100.00K in Q1 2026.
How has Vertex Pharmaceuticals's afs and trading securities - unrealized loss position (>=12 months) fair value changed year-over-year?
Vertex Pharmaceuticals's afs and trading securities - unrealized loss position (>=12 months) fair value decreased by 0.0% year-over-year, from $100.00K to $100.00K.